DOCSLIB.ORG

Globalhealth Precision State

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Globalhealth Precision State 2018 Formulary Drug List For State, Education, and Local Government Employees GlobalHealth, Inc. 701 NE 10th Street, Suite 300 Oklahoma City, OK 73104-5403 MSTDF18 Lists Updated 11/2017 www.GlobalHealth.com/state HELPFUL NUMBERS Plan Issuer: Medication Prior Authorizations: GlobalHealth, Inc. [email protected] PO Box 2393 918.878.7361 Oklahoma City, OK 73101-2393 Mail Claims to: GlobalHealth Customer Care, Language Magellan Rx Management, LLC Assistance, and Disease Management: PO Box 85042 [email protected] Richmond, VA 23261-5042 405.280.5600 (local) 1.877.280.5600 (toll-free) Mail Order Pharmacy: 711 (TTY) Magellan Rx Management, LLC Monday – Friday, 9 a.m. – 5 p.m. Central 1.800.424.1789 (toll-free) www.GlobalHealth.com/state 711 (TTY) P.O. Box 620968 Behavioral Health and Substance Use: Orlando, FL 32862 [email protected] 405.280.5600 (local) 24/7 Nurse Help Line: 1.877.280.5600 (toll-free) Information Line 711 (TTY) 1.877.280.2993 (toll-free) Monday – Friday, 9 a.m. – 5 p.m. Central www.GlobalHealth.com/state GlobalHealth Compliance Officer: 1.877.280.5852 (toll-free) Pharmacy Benefits Manager: 405.280.5852 Magellan Rx Management, LLC [email protected] Customer Service 1.800.424.1789 (toll-free) GlobalHealth Privacy Officer: 711 (TTY) 405.280.5524 [email protected] i IMPORTANT INFORMATION This formulary applies to Members who enrolled through the State, Education, and Local Government employees Plan. Member Materials Your comprehensive Member handbook has three booklets. Each one has a different purpose. These documents are important legal documents. Keep them in a safe place. Booklet Purpose Member Handbook Tells you about your benefits. for State, Education, o What benefits are covered and how much you will pay. and Local o How they are covered (including limitations and exclusions). Government o How to use them. Employees (“Member Handbook”) Physicians and Lists our Network of doctors, Facilities, and pharmacies. Health Providers Tells you if a Facility is preferred or not. Directory (“Provider Directory”) Formulary Drug List Lists drugs we cover. for State, Education, Tells you what Tier a drug is in. and Local Tells you if there are any rules to getting a drug. Government Employees (“Drug Formulary” or “Formulary”) Member materials are available on our website. Contact Customer Care for printed copies at no charge. But, be aware that the most current Drug Formulary and Provider Directory lists are on the website. This is an important legal document. Please keep it in a safe place. When this document says “we”, “us”, or “our”, it means GlobalHealth, Inc. Words or phrases that start with a capital letter are defined in the Member Handbook glossary. For specific questions about your coverage, please call the phone number printed on your Member ID card. Preferred Drugs Preferred drugs are listed in this Drug Formulary. Drugs on the list are selected based on quality (effectiveness and safety) as well as cost-effectiveness. Doctors and pharmacists have worked together to develop the Formulary, which includes generics and brand name drugs that are approved by the U. S. Food and Drug Administration (“FDA”). ii For the Member: Generic drugs contain the same active ingredients in the same amounts as brand name products. However, they may be a different color, shape, or size. For the physician: Please prescribe preferred products and allow generic substitutions when medically appropriate. Thank you. THIS DOCUMENT LIST IS EFFECTIVE AS OF THE DATE ON THE COVER. THIS LIST IS SUBJECT TO CHANGE. You may find the most current list, including any Utilization Management requirements, on our website. Contact Customer Care for printed copies. iii NOTICE ABOUT NON-DISCRIMINATION GlobalHealth, Inc. complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. GlobalHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. GlobalHealth: Provides free aids and services to people with disabilities to communicate effectively with us, such as: o Qualified sign language interpreters o Written information in other formats (large print, audio, accessible electronic formats, other formats) Provides free language services to people whose primary language is not English, such as: o Qualified interpreters o Information written in other languages If you need these services, contact the Director of Compliance and Legal Services. If you believe that GlobalHealth has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: ATTN: Director of Compliance and Legal Services, 701 NE 10th St, Ste. 300, Oklahoma City, OK 73104-5403, Fax: (405) 280-5894, or E-mail: [email protected]. You can file a grievance in person or by mail, fax, or e-mail. If you need help filing a grievance, the Compliance Attorney is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html. Language Translation Spanish ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-877-280-5600 (TTY: 711). Vietnamese CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1-877-280-5600 (TTY: 711). Chinese 注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1-877-280- 5600 (TTY: 711). Korean 주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1-877-280-5600 OR (TTY: 711)번으로 전화해 주십시오. German ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Language Translation Hilfsdienstleistungen zur Verfügung. Rufnummer: 1-877-280-5600 (TTY: 711). 117) .اتصل .إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغویة تتوافر لك بالمجان :ملحوظة Arabic 4692-082-778-1 (ھاتف الصم والبكم برقم Burmese သတိျပဳရန္ - အကယ္၍ သင္သည္ ျမန္မာစကား ကို ေျပာပါက၊ ဘာသာစကား အကူအညီ၊ အခမဲ့၊ သင့္အတြက္ စီစဥ္ေဆာင္ရြက္ေပးပါမည္။ ဖုန္းနံပါတ္ 1-877-280-5600 (TTY: 711) သုိ႔ ေခၚဆိုပါ။ Hmong LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1-877-280-5600 (TTY: 711). Tagalog PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1-877-280-5600 (TTY: 711). French ATTENTION: Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1-877-280-5600 (ATS: 711). Laotian ໂປດຊາບ: ຖ້າວ່າ ທ່ານເວ ້ າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫ ອດ້ານພາສາ, ໂດຍບໍ່ ເສັຽຄ່າ, ແມ່ນມີພ້ອມໃຫ້ ທ່ານ. ໂທຣ 1-877-280-5600 (TTY: 711). Thai เรียน: ถ ้าคุณพูดภาษาไทยคุณสามารถใชบริการช้ วยเหลือทางภาษาได่ ้ฟรี โทร 1-877-280-5600 (TTY: 711). -280-877-1 کریں کال ۔ ہیں دستیاب میں مفت خدمات کی مدد کی زبان کو آپ تو ہیں، بولتے اردو آپ اگر :خبردار Urdu 5600 (TTY: 711). Cherokee Hagsesda: iyuhno hyiwoniha [tsalagi gawonihisdi]. Call 1-877-280-5600 (TTY: 711). اگر بھ زبان فارسی گفتگو می کنید، تسھیﻻت زبانی بصورت رایگان برای شما :توجھ Persian .با تماس بگیرید .فراھم می باشد (TTY: 711) 1-877-280-5600 TIER DESCRIPTION 0 Health Care Reform 1 Generics 2 Preferred Brands 3 Non-Preferred Brands 4 Specialty Drug TYPE DESCRIPTION There is a limit on the amount of this drug that is covered per QL Quantity Limit prescription, or within a specific time frame. Your provider is required to get prior authorization before you fill PA Prior Authorization your prescription, which ensures appropriate use of the selected drug. Without prior approval, we may not cover this drug. In some cases, you may be required to first try certain drugs to treat ST Step Therapy your medical condition before you move up a “step” to other drug options. GL Gender Limit This prescription drug is restricted for a single gender. This prescription drug may only be covered if you meet the AL Age Limit minimum or maximum age limit. C Custom This drug has unique restrictions. Specialty drugs are high-cost drugs used to treat complex or rare S Specialty Drug conditions. Some examples of the diseases include; multiple sclerosis, rheumatoid arthritis, hepatitis C, and hemophilia. This medication is not on our drug list. Click on the THERAPEUTIC MED Medical Drug CLASS or sub class to find covered alternative medications. If you have questions, please contact member services. The Affordable Care Act (ACA) requires certain preventive generic HCR Health Care Reform Products products to be covered at zero dollar copay. This does not include plans that are grandfathered. PAGE 1 LAST UPDATED 10/2017 PS Preferred Specialty Preferred Specialty. HCG High Cost Generic High Cost Generic. Generic drugs available at the lowest cost. Please note the specific strengths and dosage forms; other strengths and/or dosage forms LCG Low Cost Generic of these products would be subject to the standard generic Cost- share. PAGE 2 LAST UPDATED 10/2017 LIST OF COVERED PRESCRIPTION MEDICATIONS PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS ADRENERGIC AGENTS ALPHA AND BETA ADRENERGIC AGONIST(RESPR) QL 2 / fill ADRENACLICK 3 PA ADRENALIN 3 ADYPHREN
Load more

Recommended publications
  • Multi-Drug Rapid Test Panel with Adulteration (Urine)
    6-mono-aceto-morphine in urine is 3-7 days. Multi-Drug Rapid Test Panel with 6-MAM 10 Adulteration (Urine) (6-MAM10) The Multi-Drug Rapid Test Panel yields a positive result when the concentration of (±) 3,4-Methylenedioxy- (±) 3,4-Methylenedioxy- benzodiazepines in urine exceeds detective level. Package Insert 500 Buprenorphine (BUP) Amphetamine(MDA500) Amphetamine Instruction Sheet for testing of any combination of the following drugs: Ethyl- β-D-Glucuronide(ETG500) Ethyl- β -D-Glucuronide 500 Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is ACE/AMP/BAR/BZO/BUP/COC/THC/MTD/MET/MDMA/MOP/MQL/OPI/PCP/PPX/TCA/TML/K sold under the trade names Subutex™, Buprenex™, Temgesic™ and Suboxone™, which ET/OXY/COT/EDDP/FYL/K2/6-MAM/MDA/ETG/CLO/LSD/MPD/ZOL Ethyl- β-D-Glucuronide(ETG1,000) Ethyl- β -D-Glucuronide 1,000 contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeutically, Including Specimen Validity Tests (S.V.T.) for: Clonazepam(CLO 400) Clonazepam 400 Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a Oxidants/PCC, Specific Gravity, pH, Nitrite, Glutaraldehyde and Creatinine Clonazepam(CLO 150) Clonazepam 150 form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or A rapid test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in identical substance to the drug normally used. In substitution therapy, Buprenorphine is as human urine. For healthcare professionals including professionals at point of care sites. Lysergic Acid Diethylamide (LSD) Lysergic Acid Diethylamide 20 effective as Methadone but demonstrates a lower level of physical dependence.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Pureweigh®-FM
    Manufacturers of Hypo-al ler gen ic Nutritional Sup ple ments PureWeigh®-FM INTRODUCED 2000 What Is It? than DHEA in stimulating the thermogenic enzymes of the liver, helping to support a leaner BMI (Body Mass PureWeigh®-FM is an encapsulated supplement companion Index) and healthy weight control. In a double blind to PureWeigh® PREMEAL Beverage containing banaba study involving 30 overweight adults, 7-KETO supported (Lagerstroemia speciosa L.) extract, green tea extract, healthy body composition and BMI when combined with taurine, 7-KETO™ DHEA, biotin, magnesium citrate and exercise.* chromium polynicotinate. PureWeigh®-FM may also be used independently of PureWeigh® PREMEAL Beverage to support • Biotin, facilitating protein, fat and carbohydrate healthy glucose metabolism and promote weight loss.* metabolism by acting as a coenzyme for numerous metabolic reactions. A clinical study reported that high Features Include dose administration of biotin helped promote healthy glucose metabolism. A number of animal studies support • Banaba extract, containing a triterpenoid compound this claim. Biotin may also act to promote transcription called corosolic acid, reported in studies to support and translation of glucokinase, an enzyme found in the healthy glucose function and absorption. A recent liver and pancreas that participates in the metabolism phase II, double-blind, placebo-controlled multi-center of glucose to form glycogen. In addition, a double-blind trial in Japan suggested that banaba extract maintained study reported that biotin supplementation may promote healthy glucose function and was well tolerated by healthy lipid metabolism, citing an inverse relationship volunteers. Furthermore, an independent U.S. between plasma biotin and total lipids.* preliminary clinical study reported statistically significant weight loss in human volunteers • Magnesium citrate, providing a highly bioavailable supplementing with a 1% corosolic acid banaba extract.
    [Show full text]
  • Applications of in Silico Methods to Analyze the Toxicity and Estrogen T Receptor-Mediated Properties of Plant-Derived Phytochemicals ∗ K
    Food and Chemical Toxicology 125 (2019) 361–369 Contents lists available at ScienceDirect Food and Chemical Toxicology journal homepage: www.elsevier.com/locate/foodchemtox Applications of in silico methods to analyze the toxicity and estrogen T receptor-mediated properties of plant-derived phytochemicals ∗ K. Kranthi Kumara, P. Yugandharb, B. Uma Devia, T. Siva Kumara, N. Savithrammab, P. Neerajaa, a Department of Zoology, Sri Venkateswara University, Tirupati, 517502, India b Department of Botany, Sri Venkateswara University, Tirupati, 517502, India ARTICLE INFO ABSTRACT Keywords: A myriad of phytochemicals may have potential to lead toxicity and endocrine disruption effects by interfering Phytochemicals with nuclear hormone receptors. In this examination, the toxicity and estrogen receptor−binding abilities of a QSAR modeling set of 2826 phytochemicals were evaluated. The endpoints mutagenicity, carcinogenicity (both CAESAR and ISS Toxicity models), developmental toxicity, skin sensitization and estrogen receptor relative binding affinity (ER_RBA) Nuclear hormone receptor binding were studied using the VEGA QSAR modeling package. Alongside the predictions, models were providing pos- Self−Organizing maps sible information for applicability domains and most similar compounds as similarity sets from their training Clustering and classification schemes sets. This information was subjected to perform the clustering and classification of chemicals using Self−Organizing Maps. The identified clusters and their respective indicators were considered as potential hotspot structures for the specified data set analysis. Molecular screening interpretations of models wereex- hibited accurate predictions. Moreover, the indication sets were defined significant clusters and cluster in- dicators with probable prediction labels (precision). Accordingly, developed QSAR models showed good pre- dictive abilities and robustness, which observed from applicability domains, representation spaces, clustering and classification schemes.
    [Show full text]
  • NORPRAMIN® (Desipramine Hydrochloride Tablets USP)
    NORPRAMIN® (desipramine hydrochloride tablets USP) Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of NORPRAMIN or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. NORPRAMIN is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use.) DESCRIPTION NORPRAMIN® (desipramine hydrochloride USP) is an antidepressant drug of the tricyclic type, and is chemically: 5H-Dibenz[bƒ]azepine-5-propanamine,10,11-dihydro-N-methyl-, monohydrochloride. 1 Reference ID: 3536021 Inactive Ingredients The following inactive ingredients are contained in all dosage strengths: acacia, calcium carbonate, corn starch, D&C Red No. 30 and D&C Yellow No. 10 (except 10 mg and 150 mg), FD&C Blue No. 1 (except 25 mg, 75 mg, and 100 mg), hydrogenated soy oil, iron oxide, light mineral oil, magnesium stearate, mannitol, polyethylene glycol 8000, pregelatinized corn starch, sodium benzoate (except 150 mg), sucrose, talc, titanium dioxide, and other ingredients.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION (−)-Epigallocatechin Gallate Item No. 70935 CAS Registry No.: 989-51-5 Formal Name: 3,4-dihydro-5,7-dihydroxy-2R-(3,4,5- OH trihydroxyphenyl)-2H-1-benzopyran-3R- OH yl-3,4,5-trihydroxy-benzoate H HO O Synonym: EGCG OH MF: C22H18O11 O FW: 458.4 H OH OH Purity: ≥96% O UV/Vis.: λmax: 276 nm Supplied as: A crystalline solid OH Storage: -20°C OH Stability: ≥2 years Item Origin: Plant/Folium camelliae Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures (−)-Epigallocatechin gallate (EGCG) is supplied as a crystalline solid. A stock solution may be made by dissolving the EGCG in an organic solvent purged with an inert gas. EGCG is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of EGCG in these solvents is approximately 20, 25, and 30 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of EGCG can be prepared by directly dissolving the crystalline compound in aqueous buffers. The solubility of EGCG in PBS (pH 7.2) is approximately 25 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description EGCG is a phenol that has been found in green and black tea plants and has diverse biological activities.1-7 1 It is lytic against T.
    [Show full text]
  • Sulfhydryl Reduction of Methylene Blue with Reference to Alterations in Malignant Neoplastic Disease
    Sulfhydryl Reduction of Methylene Blue With Reference to Alterations in Malignant Neoplastic Disease Maurice M. Black, M. D. (From the Department of Biochemistry, New York Medical College, New York 29, N. t;., and the Brooklyn Cancer Institute, Brooklyn 9, N. Y.) (Received for publication May 8, 1947) A significant decrease in methylene blue re- reactivity is less than half that of the cysteine. It is ducing power of plasma from patients with malig- noteworthy also that the resultant leuco mixture nant neoplastic disease was previously reported did not revert back to colored methylene blue on (1). At that time it was suggested that change in a cooling, as was the case with methylene blue re- reducing group of the albumin molecule was a duction by plasma. likely source of this alteration. Similar conclusions Similar relationships were investigated between were reported also by Savignac and associates (7) cysteine and different concentrations of methylene as the result of analogous studies. blue. As seen in Fig. 2, similar curves are obtained, In an attempt to evaluate the effect of the sulf- but the position of the curve on the graph varies hydryl group on the reduction of methylene blue, a with the concentration of the methylene blue used. study was undertaken with various compounds of It should be noted that there is no appreciable known -SH and S-S structures. In addition, an difference in the reducing time of methylene blue attempt was made to establish a standard method on varying the concentrations between 0.10 per of calibration of various lots of methylene blue, so cent and 0.2 per cent, although 0.08 per cent shows that more uniform results would be possible in the a decided difference.
    [Show full text]
  • Treatment of Methaemoglobinemia in Dogs Following Ingestion of Baits Containing PAPP
    Treatment of methaemoglobinemia in dogs following ingestion of baits containing PAPP Introduction A new toxin for wild dog and fox management has been released in Australia. Known as DOGABAIT and FOXECUTE®, the new baits contain the chemical para-aminopropiophenone (or ‘PAPP’), which induces methaemoglobinemia following ingestion. Veterinarians may be presented with cases of off-target poisoning of domestic pets, and so need to be aware of the mode of action of the toxin and its antidote, in order to attempt management of these cases. Foxecute bait dosage is 400mg and Dogabait dosage is 1000mg of PAPP. Knowing which of these baits has been accidentally ingested may help with clinical decision making and determination of appropriate antidote dosage. General considerations - methaemoglobinemia Methaemoglobin occurs as the result of oxidative damage to haemoglobin, which can be induced in cats and dogs by several chemicals, e.g. naphthalene (mothballs), onions and garlic (typically in dogs after a BBQ) and paracetamol (especially in cats).1,2 Local anaesthetics, such as benzocaine, can also cause significant methaemoglobinemia if not carefully administered.2,3 The chemical PAPP in the new baits bio-transforms in the liver of eutherian carnivores to a metabolite that rapidly oxidises haemoglobin to methaemoglobin. Clinical signs Clinical signs of methaemoglobinemia include lethargy, cyanosis, ataxia, unresponsiveness, unconsciousness and death. Blood containing high concentrations of methaemoglobin is chocolate brown in colour (Figure 1) and cannot transport oxygen efficiently. Minor amounts of methaemoglobin in the blood may be reduced back to active haemoglobin by innate enzyme systems. However, significant haemoglobin oxidation can disable oxygen transport to the point of hypoxia, anoxia, and death.
    [Show full text]
  • Possible Involvement of Nitric Oxide (NO) Signaling Pathway in the Anti- Depressant-Like Effect of MK-801(Dizocilpine), a NMDA R
    Indian Journal of Experimental Biology Vol. 46, March 2008, pp 164-170 Possible involvement of nitric oxide (NO) signaling pathway in the anti- depressant-like effect of MK-801(dizocilpine), a NMDA receptor antagonist in mouse forced swim test Ashish Dhir & SK Kulkarni* Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India Received 27 November 2007; revised 15 January 2008 L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) is an important signaling pathway involved in depression. With this information, the present study aimed to study the involvement of this signaling pathway in the antidepressant-like action of MK-801 (dizocilpine; N-methyl-d-aspartate receptor antagonist) in the mouse forced-swim test. Total immobility period was recorded in mouse forced swim test for 6 min. MK-801 (5-25 μg/kg., ip) produced a U- shaped curve in reducing the immobility period. The antidepressant-like effect of MK-801 (10 μg/kg, ip) was prevented by pretreatment with L-arginine (750 mg/kg, ip) [substrate for nitric oxide synthase (NOS)]. Pretreatment of mice with 7-nitroindazole (7-NI) (25 mg/kg, ip) [a specific neuronal nitric oxide synthase inhibitor] produced potentiation of the action of subeffective dose of MK-801 (5 μg/kg, ip). In addition, treatment of mice with methylene blue (10 mg/kg, ip) [direct inhibitor of both nitric oxide synthase and soluble guanylate cyclase] potentiated the effect of MK-801 (5 μg/kg, ip) in the forced-swim test. Further, the reduction in the immobility period elicited by MK-801 (10 μg/kg, ip) was also inhibited by pretreatment with sildenafil (5 mg/kg, ip) [phosphodiesterase 5 inhibitor].
    [Show full text]
  • Effect of Epigallocatechin-3-Gallate, Major Ingredient of Green Tea, on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers
    Journal name: Drug Design, Development and Therapy Article Designation: Original Research Year: 2017 Volume: 11 Drug Design, Development and Therapy Dovepress Running head verso: Kim et al Running head recto: Effect of green tea on the pharmacokinetics of rosuvastatin open access to scientific and medical research DOI: http://dx.doi.org/10.2147/DDDT.S130050 Open Access Full Text Article ORIGINAL RESEARCH Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers Tae-Eun Kim1 Abstract: Previous in vitro studies have demonstrated the inhibitory effect of green tea on Na Ha2 drug transporters. Because rosuvastatin, a lipid-lowering drug widely used for the prevention of Yunjeong Kim2 cardiovascular events, is a substrate for many drug transporters, there is a possibility that there Hyunsook Kim1 is interaction between green tea and rosuvastatin. The aim of this study was to investigate the Jae Wook Lee3 effect of green tea on the pharmacokinetics of rosuvastatin in healthy volunteers. An open-label, Ji-Young Jeon2 three-treatment, fixed-sequence study was conducted. On Day 1, 20 mg of rosuvastatin was given to all subjects. After a 3-day washout period, the subjects received 20 mg of rosuvastatin Min-Gul Kim2,4 plus 300 mg of epigallocatechin-3-gallate (EGCG), a major ingredient of green tea (Day 4). 1 Department of Clinical After a 10-day pretreatment of EGCG up to Day 14, they received rosuvastatin (20 mg) plus Pharmacology, Konkuk University Medical Center, Seoul, 2Center for EGCG (300 mg) once again (Day 15). Blood samples for the pharmacokinetic assessments Clinical Pharmacology, Biomedical were collected up to 8 hours after each dose of rosuvastatin.
    [Show full text]
  • Methylene Blue Methylene Blue (Tetramethylthionine Chloride) Is a Blue Dye That Is Used for the Treatment of Methemoglobinemia
    February 2015 Poison Center Hotline: 1-800-222-1222 The Maryland Poison Center’s Monthly Update: News, Advances, Information Methylene Blue Methylene blue (tetramethylthionine chloride) is a blue dye that is used for the treatment of methemoglobinemia. Methemoglobinemia is defined as a blood me- themoglobin level above 1% and can be caused by chemicals that oxidize Fe2+ to Fe3+ in hemoglobin. This oxidized form of hemoglobin is called methemoglobin and has poor oxygen carrying capacity. Causes include nitrites and nitrates (found in preserved meats and well water contaminated with fertilizer), local anesthetics (e.g. teething gels, benzocaine spray), aniline dyes, antimalarials, and dapsone. Inducers of methemoglobinemia are usually ingested rather than inhaled. Methylene blue is an effective antidote for methemoglobinemia due to its own oxidizing properties. It oxidizes NADPH, forming the reduced product leukometh- ylene blue. Leukomethylene blue in turn acts as a reducing agent converting me- themoglobin to hemoglobin and thus restoring oxygen carrying capacity. Meth- ylene blue is indicated in patients with symptomatic methemoglobinemia (e.g. cyanosis, dyspnea, confusion, seizures, coma, metabolic acidosis, dark or brown Did you know? blood), usually occurring at methemoglobin levels of >20-30%. Those with high Methylene blue has been used risk comorbidities (anemia, CHF, pneumonia, angina) may require methylene blue in the treatment of refractory at lower methemoglobin levels. shock? Dosing for methylene blue is 1-2 mg/kg (0.1 to 0.2 mL/kg) of a 1% solution admin- istered intravenously over five minutes. The neonatal dose is 0.3-1 mg/kg. Admin- There is evidence that methylene istration is followed by a 15mL-30mL fluid flush to reduce local pain, as IV meth- blue may be useful for the ylene blue is highly irritating to tissue.
    [Show full text]
  • Reducing Toxic Reactive Carbonyl Species in E-Cigarette Emissions
    RSC Advances View Article Online PAPER View Journal | View Issue Reducing toxic reactive carbonyl species in e- cigarette emissions: testing a harm-reduction Cite this: RSC Adv., 2020, 10,21535 strategy based on dicarbonyl trapping Bruna de Falco, †af Antonios Petridis,†ac Poornima Paramasivan,b Antonio Dario Troise, de Andrea Scaloni,e Yusuf Deeni,b W. Edryd Stephens*c and Alberto Fiore *a Reducing the concentration of reactive carbonyl species (RCS) in e-cigarette emissions represents a major goal to control their potentially harmful effects. Here, we adopted a novel strategy of trapping carbonyls present in e-cigarette emissions by adding polyphenols in e-liquid formulations. Our work showed that the addition of gallic acid, hydroxytyrosol and epigallocatechin gallate reduced the levels of carbonyls formed in the aerosols of vaped e-cigarettes, including formaldehyde, methylglyoxal and glyoxal. Liquid chromatography mass spectrometry analysis highlighted the formation of covalent adducts between Creative Commons Attribution 3.0 Unported Licence. aromatic rings and dicarbonyls in both e-liquids and vaped samples, suggesting that dicarbonyls were formed in the e-liquids as degradation products of propylene glycol and glycerol before vaping. Short- Received 6th March 2020 term cytotoxic analysis on two lung cellular models showed that dicarbonyl-polyphenol adducts are not Accepted 29th May 2020 cytotoxic, even though carbonyl trapping did not improve cell viability. Our work sheds lights on the DOI: 10.1039/d0ra02138e ability of polyphenols to trap RCS in high carbonyl e-cigarette emissions, suggesting their potential value rsc.li/rsc-advances in commercial e-liquid formulations. Introduction smoking-related symptoms and conditions to become manifest, This article is licensed under a it is too early to evaluate the long-term clinical effects of vaping The use of e-cigarettes is a major issue in public health.
    [Show full text]